B 1344
Alternative Names: B-1344Latest Information Update: 28 Jun 2024
At a glance
- Originator Shanghai Institute of Nutrition and Health
- Developer Tasly Pharmaceutical Group
- Class Fibroblast growth factors; Hepatoprotectants
- Mechanism of Action Fibroblast growth factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis
- No development reported Non-alcoholic fatty liver disease
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Non-alcoholic-fatty-liver-disease in China (Parenteral)
- 30 Aug 2022 Phase-I clinical trials in Non-alcoholic steatohepatitis (In volunteers) in USA (SC) (NCT05655221)
- 12 Jun 2020 Pharmacodynamics data from a preclinical trials in Nonalcoholic steatohepatitis and Non-alcoholic fatty liver disease presented at the 80th Annual Scientific Sessions of the American Diabetes Association